Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...
Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
GlobalData on MSN6d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...
The company reported a robust set of numbers for the December quarter of FY25, with its profit nearly doubling year-on-year ...
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...
An unassuming painkiller that most people have in their cupboard could help prevent the spread of cancer. Experts might have ...
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback